Recently at ASCO 2019, ETNA investigators reported that the secondary endpoint of 5-year EFS was not statistically significantly different between neoadjuvant nab-paclitaxel compared to s-paclitaxel.

LONDON, England—While it’s not clear sirolimus-based devices will ever overtake the old workhorse paclitaxel, data from several studies presented here at the 2025 Charing Cross International Symposium ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

IN A MAJOR victory for cancer treatment in South Africa, Eurolab was granted the right to continue making and selling generic prostate cancer medication in the country at an affordable price ...

The phase III trial, which enrolled 2233 patients, compared two dose-dense chemotherapy regimens: Weekly nab-paclitaxel (125 mg/m 2 for eight cycles) vs biweekly solvent-based paclitaxel (175 mg/m ...

WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...

Before you have atezolizumab you have tests on your cancer cells to check your cancer has enough of the PD-L1 protein. Nab-paclitaxel is a chemotherapy drug. It combines the chemotherapy drug ...

Apple's next big event is scheduled in a few days and now reports indicate that Apple could be planning to discontinue its popular EarPods soon. The new iPhone 16 series, Apple Watch Series 10 ...

12 years after Apple's EarPods were introduced with the iPhone 5, the company may finally discontinue its $19 wired earbuds. Apple's EarPods were first introduced in 2012 as the standard earphones ...

While paclitaxel is initially effective for many patients, resistance to the drug commonly develops within five to seven months, leading to disease progression and limited treatment options.

The cancer drug paclitaxel has captured the imaginations of chemists for decades, in part because of its complex polycyclic core with an oxetane ring. Although scientists have synthesized the ...

to receive GEMPAX (paclitaxel 80 mg/m 2 + gemcitabine 1,000 mg/m 2; IV; once at day (D) 1, D8, and D15/arm A) or gemcitabine (arm B) alone once at D1, D8, and D15 every 28 days until progression, ...